Cerus (CERS) AI Stock Analysis

• Market Cap: $259.98M
• Dividend Yield: N/A
• Average Volume (3M): 977.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.39
• Revenue Growth: 13.06%
• EPS Growth: 41.50%
• Country: US
• Employees: 614
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 191,160,480
• 10 Day Avg. Volume: 835,324
• 30 Day Avg. Volume: 977,838
• PEG Ratio: -1.48
• Price to Book (P/B): 4.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 38.91
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 0.48
• Enterprise Value/Gross Profit: 3.26
• Enterprise Value/Ebitda: -8.81
• 1Y Price Target: $4.67
• Price Target Upside: 243.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 59 Neutral
• Price Target: $1.50 ▲(10.29%Upside)

Cerus Corporation's stock score is driven by strong revenue growth and positive cash flow trends, as highlighted in the earnings call. However, persistent net losses and negative valuation metrics weigh down the score. Mixed technical indicators and macroeconomic challenges such as tariffs further contribute to a cautious outlook.

Positive Factors

Product Development

Cerus landed CE Mark for its next-generation Illuminator well ahead of expectations, marking a source of upside to guidance.

Profitability

Cerus delivered positive adjusted EBITDA of $5.7M for the full year, indicating a productive quarter from a profitability standpoint.

Regulatory Progress

TUV-SUD completed review of the INTERCEPT RBC clinical module, expanding its CE Mark submission to all patient indications, signaling positive momentum in securing regulatory clearance.

Revenue Growth

Strength in North America and IFC propelled Cerus to 13% revenue growth.

Negative Factors

Regional Performance

Growth was partially offset by a decline of 4% in the company's EMEA segment, largely due to the impact of foreign exchange.

Regulatory Setback

The CE mark review for INTERCEPT RBCs in Europe concluded without an approval, marking a disappointing setback for the company.

Cerus Business Overview & Revenue Model

Company Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

How the Company Makes Money

Cerus Corporation generates revenue primarily through the sale of its INTERCEPT Blood System, which includes kits, devices, and consumables used for pathogen inactivation in blood components like platelets and plasma. The company earns money by supplying these systems to blood centers and hospitals worldwide, who are the primary customers. Additionally, Cerus engages in strategic partnerships and collaborations with various healthcare organizations and government entities, which can lead to funding, grants, or joint ventures that support product development and market expansion. Revenue is also influenced by regulatory approvals and the adoption of blood safety protocols that mandate or recommend the use of systems like INTERCEPT.

Cerus Financial Statement Overview

Summary

Cerus shows solid revenue growth and healthy gross margins at 56%, but continues to face profitability challenges with a net profit margin of -10.23%. The balance sheet indicates manageable leverage with a debt-to-equity ratio of 0.62, yet ROE remains negative. Positive cash flow trends, with an operating cash flow to net income ratio of -0.45, suggest effective cash management, laying groundwork for future profitability.

Income Statement

Cerus has shown a steady increase in revenue over the years, with a TTM revenue growth rate of 2.71% from the previous annual report. Gross profit margin is healthy at 56.00% for TTM, indicating efficient cost management on direct expenses. However, the company is still operating at a net loss, with a net profit margin of -10.23% and a negative EBIT and EBITDA margin, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a debt-to-equity ratio of 0.62, which is manageable but indicates some leverage risk. The equity ratio stands at 26.84%, signifying that a substantial portion of the company's assets are financed through equity. ROE is negative due to net losses, pointing to challenges in generating returns for shareholders.

Cash Flow

Cash flow statement analysis shows positive operating cash flow, with an operating cash flow to net income ratio of -0.45, highlighting better cash flow management compared to earnings. The free cash flow growth rate is encouraging at -21.32% over the last year, indicating efforts towards improving cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	180.27M	156.37M	162.05M	130.86M	91.92M
Gross Profit	99.52M	86.40M	87.09M	67.38M	50.76M
EBITDA	-9.88M	-26.54M	-34.08M	-45.99M	-51.37M
Net Income	-20.92M	-37.49M	-42.83M	-54.38M	-59.86M
Balance Sheet
Total Assets	200.92M	197.75M	218.09M	237.50M	221.41M
Cash, Cash Equivalents and Short-Term Investments	80.45M	65.85M	102.15M	129.36M	133.59M
Total Debt	98.10M	96.00M	87.24M	87.59M	66.89M
Total Liabilities	144.02M	144.30M	149.53M	151.88M	117.61M
Stockholders Equity	56.15M	52.65M	67.61M	84.62M	103.81M
Cash Flow
Free Cash Flow	8.52M	-47.77M	-27.61M	-34.83M	-42.36M
Operating Cash Flow	11.36M	-43.17M	-25.61M	-33.92M	-40.74M
Investing Cash Flow	-8.13M	8.62M	8.46M	12.69M	-49.56M
Financing Cash Flow	4.96M	10.67M	4.19M	34.29M	91.78M

Cerus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Positive. The current price of 1.36 is below the 20-day moving average (MA) of 1.43, below the 50-day MA of 1.38, and below the 200-day MA of 1.56, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.33 is Neutral, neither overbought nor oversold. The STOCH value of 35.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CERS.

Cerus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZIMV	67 Neutral	$529.61M	―	-6.35%	―	-32.70%	94.89%
CERS	59 Neutral	$259.98M	―	-36.14%	―	13.06%	41.50%
RCEL	55 Neutral	$165.48M	―	-407.50%	―	32.24%	-66.93%
SNWV	55 Neutral	$315.01M	―	0.65%	―	61.50%	34.99%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
LUNG	52 Neutral	$133.45M	―	-60.68%	―	19.84%	5.77%
NNOX	46 Neutral	$347.50M	―	-30.11%	―	15.32%	15.73%

Cerus Corporate Events

Cerus Appoints New Chair Following Board Retirement

On June 16, 2025, Daniel N. Swisher, Jr., the chair of the board of directors at Cerus Corporation, announced his immediate retirement from the Board and all related committees. His departure was not due to any disagreements with the company. Subsequently, on June 20, 2025, the Board appointed William M. Greenman, the company’s President and CEO, as the new chair of the Board, and Frank Witney, Ph.D., as the lead independent director, both effective immediately.

The most recent analyst rating on (CERS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.

Cerus Stockholders Approve Key Proposals at Annual Meeting

On June 3, 2025, Cerus Corporation held its 2025 Annual Meeting of Stockholders, where several key proposals were voted upon. Stockholders approved the amendment and restatement of the company’s 2024 Equity Incentive Plan, elected two board members, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CERS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.